Preoperative HE4 Tumor Marker and Prognostic Factors in Endometrial Cancer: Review Article


  • A. Espiau Romera Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain
  • L. Baquedano Mainar Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain
  • M.J. Puente Luján Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain
  • R. Laborda Gotor Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain
  • L. Ruiz Campo Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain
  • M.A. Ruiz Conde Department of Gynecology, Miguel Servet University Hospital, Zaragoza, Spain



Endometrial Neoplasms, HE4, Lymphatic Metastasis.


Purpose of the Review: The aim of the review is to summarize the current evidence of HE4 tumor marker as a prognostic marker of endometrial cancer since it is a novel and not yet validated marker in the management of this neoplasm.

Recent Findings: HE4 has been studied as a preoperative prognosis marker and the result is encouraging as it is statistically related to unfavorable prognostic markers in endometrial cancer. Having a preoperative marker that relates with prognosis is a non invasive and cost-effective way to classify the patients before the surgery act.

Summary: Clinicians could use HE4 as a prognostic marker to help them in the preoperative decision-making process. Thus, good prognostic patients with a low serum HE4 could have a less invasive surgery avoiding lymphadecnectomy which decrease the morbidity of the procedure and reducing the operative time.


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018; 68(6): 394-424. DOI:

Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Advances in Experimental Medicine and Biology 2017; 3-46. DOI:

Huang G-Q, Xi Y-Y, Zhang C-J, Jiang X. Serum Human Epididymis Protein 4 Combined with Carbohydrate Antigen 125 for Endometrial Carcinoma Diagnosis: A Meta-Analysis and Systematic Review. Genetic Testing and Molecular Biomarkers 2019; 23(8): 580-8. DOI:

Presl J, Ovesna P, Novotny Z, Vlasak P, Bouda J, Kostun JAN. Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management. Anticancer Research 2017; 37(5): 2697-702. DOI:

Stiekema A, Lok C, Korse CM, van Driel WJ, van der Noort V, Kenter GG. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Virchows Arch 2017; 470(6): 655-64. DOI:

Benati M, Montagnana M, Danese E, Paviati E, Giudici S, Ruzzenente O. The clinical significance of DJ-1 and HE4 in patients with endometrial cancer. Journal of Clinical Laboratory Analysis 2018; 32(1): 1-5. DOI:

Li Y, Cong P, Wang P, Peng C, Liu M, Sun G. Risk factors for pelvic lymph node metastasis in endometrial cancer. Archives of Gynecology and Obstetrics 2019; 300(4): 1007- 13. DOI:

“Oncoguía SEGO: Cáncer de Endometrio. Guía De Práctica Clínica en Cáncer Ginecológico y Mamario. Progresos en Obstetricia y Ginecología 2016; 60(3): 274-302.

Colombo N, Creutzberg C, Amant F, Bosse T, González- Martín A, Ledermann J. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology 2015; 117(3): 559-81. DOI:

Wang Y, Han C, Teng F, Bai Z, Tian W, Xue F. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer. International Journal of Gynecology & Obstetrics 2017; 136(1): 58-63. DOI:

Bosse T, Peters EEM, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JWM. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials. European Journal of Cancer 2015; 51(13): 1742-50. DOI:

Capriglione S, Plotti F, Miranda A, Lopez S, Scaletta G, Moncelli M. Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. Expert Review of Anticancer Therapy 2017; 17(1): 9-18. DOI:

Qu W, Gao Q, Chen H, Tang Z, Zhu X, Jiang S-W. HE4-test of urine and body fluids for diagnosis of gynecologic cancer. Expert Review of Molecular Diagnostics 2017; 17(3): 239-44. DOI:

Li L, Zhu Y, Zhong Y, Su T, Fan X, Xi Q. Human epididymis protein 4 in endometrial cancer: A meta-analysis. Clinica Chimica Acta 2018; 482: 215-23. DOI:

Gorp T Van, Cadron I, Despierre E, Daemen A, Leunen K, Amant F. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer 2011; 104: 863-70. DOI:

Abbink K, Zusterzeel PL, Geurts-Moespot AJ, Herwaarden AE van, Pijnenborg JM, Sweep FC. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumor Biology 2018; 40(2): 1- 10. DOI:

Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clinical Chemistry and Laboratory Medicine 2012; 50(12): 2189-98. DOI:

Capriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumor Biology 2015; 36(6): 4151-6. DOI:

Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumor Biology 2013; 34(1): 571-6. DOI:

Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Bioloy 2013; 34(5): 2645-50. DOI:

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. British Journal of Cancer 2011; 104(9): 1418-25. DOI:

Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. American Journal of Obstetrics & Gynecology 2013; 209(2): 142.e1-142.e6. DOI:

Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecologic Oncology 2012; 124(2): 270-5. DOI:

Abdalla N, Piórkowski R, Stanirowski P, Słomka A, Cendrowski K, Sawicki W. Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer. Menopause Review 2016; 15(3): 133-7. DOI:

Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of Tumor Marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. International Journal of Gynecological Cancer 2011; 21(7): 1185-90. DOI:

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecologic Oncology 2012; 126(2): 186-91. DOI:

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology 2008; 110(2): 196-201. DOI:




How to Cite

A. Espiau Romera, L. Baquedano Mainar, M.J. Puente Luján, R. Laborda Gotor, L. Ruiz Campo, & M.A. Ruiz Conde. (2019). Preoperative HE4 Tumor Marker and Prognostic Factors in Endometrial Cancer: Review Article . Journal of Analytical Oncology, 8, 39–42.